Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET INCOME (LOSS) PER SHARE (Tables)

NET INCOME (LOSS) PER SHARE (Tables)

9 Months Ended

Sep. 30, 2022

Schedule of computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share (in thousands except per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
EPS Numerator:
Net income (loss)	$	(19,037)	$	(20,952)	$	(59,974)	$	4,727
EPS Denominator—Basic and Diluted:
Weighted-average common shares outstanding		172,836		170,886		172,256		170,297
EPS Denominator—Diluted:
Weighted-average common shares outstanding		172,836		170,886		172,256		170,297
Dilutive effect of stock options, restricted stock units and shares under Purchase Plan		—		—		—		6,155
Weighted-average shares outstanding and common stock equivalents		172,836		170,886		172,256		176,452

Net income (loss) per share
Basic	$	(0.11)	$	(0.12)	$	(0.35)	$	0.03
Diluted	$	(0.11)	$	(0.12)	$	(0.35)	$	0.03

Schedule of antidilutive securities

The potential shares of common stock that were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive are as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Outstanding stock options		32,687		30,490		32,687		9,450
Restricted stock units		1,174		234		1,174		4
Purchase Plan		398		313		398		—
Total		34,259		31,037		34,259		9,454